Sophie Shulman

3 days ago | calcalistech.com | Sophie Shulman

eToro is closing its IPO order books on Monday due to exceptionally high demand, Calcalist has learned. The underwriters of the IPO, led by Goldman Sachs and Jefferies, notified participants in the Israeli fintech company's roadshow that they will no longer be accepting new orders. The offering is estimated to be more than ten times oversubscribed.

4 days ago | calcalist.co.il | Sophie Shulman

Jon Gray, true to his bold instincts—if not his understated name or appearance—has built a career on audacious moves. Last week, the American financier made headlines with a staggering $125 million donation to Tel Aviv University’s Faculty of Medicine, the largest in the institution’s history and among the most significant ever in Israeli academia. Gray’s name first became widely known for another outsized bet: the $26 billion acquisition of Hilton Hotels just before the 2008 financial crisis.

4 days ago | calcalistech.com | Sophie Shulman

The Blackstone President talks philanthropy, politics, and why he and his wife Mindy chose to support Israeli medical education after October 7. 11:59, 11.05.25 TAGS:Jonathan GrayBlackstoneTel Aviv UniversityJon Gray, true to his bold instincts—if not his understated name or appearance—has built a career on audacious moves.

1 week ago | calcalist.co.il | Sophie Shulman

Teva Pharmaceuticals offered a long-awaited explanation for the sharp 10% jump in its share price last week. But the gains come at a steep human cost. The Israeli drugmaker reassured investors with a revised, more optimistic profit forecast—after a previous one had triggered widespread concern and a selloff earlier this year. Yet buried deep in the investor presentation, almost as an afterthought on slide 15, Teva revealed that it plans to lay off 8% of its global workforce over the next 18 months.

1 week ago | calcalistech.com | Sophie Shulman

CEO signals this is ‘just the first step’ in multi-year effort to streamline and scale. 10:08, 08.05.25 TAGS:PharmaceuticalsLayoffsTevaTeva Pharmaceuticals offered a long-awaited explanation for the sharp 10% jump in its share price last week. But the gains come at a steep human cost. The Israeli drugmaker reassured investors with a revised, more optimistic profit forecast—after a previous one had triggered widespread concern and a selloff earlier this year.